Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester and Editor‑in‑Chief at Blood Cancer Journal, shared a post on X:
“Here are my Top 5 ASH25 myeloma abstracts.
My Top 5 are based on new data, clinical impact, & methodology with links to the full abstract. Bookmark! Thread with countdown.
5. Stem cell boost as treatment for cytopenias after CART. Cindy Varga et al.
Highly effective, safe, and practical.
Abstract Title: Outcomes of stem cell boost (SCB) versus supportive care alone for prolonged cytopenias after chimeric antigen receptor T cell therapy (CAR-T) in relapsed/refractory multiple myeloma (RRMM): A muli-center real-world analysis
Category: 600s – Hematologic Malignancy
Authors: Cindy Varga, Myra Robinson, James Davis, Hamza Hashmi, Thomas Martin, Anupama Kumar, Douglas Sborov, Charlotte Wagner, Doris Hansen, Omar Alexis Castaneda Puglianini, Leyla Shune, Evguenia Bhurtel, Aimaz Afrough, Larry Anderson, Binod Dhakal, Megan Herr, Shambavi Richard, Alex Lieberman-Cribbin, Daniel Sherbenou, Peter Forsberg, Sneha Purvey, Jack Khouri, Yi Lin, Surbhi Sidana, Shonali Midha, Asad Haider, Krina Patel, Mehmet Kocoglu, Christopher Ferreri
4. In vivo CAR-T for myeloma: inMMyCAR phase 1 study of KLN-1010. Simon Harrison, Joy Ho et al.
Off the shelf CART— made possible by selective transduction of T cells in vivo with lentiviral vector. Only 3 patients in abstract but chosen as LBA for its novelty.
Abstract Title: Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): Preliminary results from inMMyCAR, the first-inhuman phase 1 study of KLN-1010
Category: 700s – Transplantation and Adoptive Cell Therapies
Authors: Simon Harrison, Phoebe Joy Ho, Sueh-Li Lim, Stephanie Talam, Hannah Pahl, Dharmesh Dingar, Scott Currence, Travis Quigley, Andrew Spencer
3. Phase III COBRA trial VRd vs KRd. Dytfeld et al.
RCT with 250 patients showing better outcomes with KRd vs VRd. Goes against ECOG ENDURANCE trial where we found no difference. But not sure how this fits since we have moved to Dara VRd.
Abstract Title: Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma (NDMM) – interim results from the randomized Phase III COBRA trial.
Category: 600s – Hematologic Malignancy
Authors: Dominik Dytfeld, Tadeusz Kubicki, Agata Tyczynska, Marcin Rymko, Krzysztof Jamroziak, Fredrik Schjesvold, Jaroslaw Piszcz, Tomasz Wrobel, Krzysztof Giannopoulos, Bartosz Pula, Agnieszka Konska, Pawel Steckiewicz, Juha Lievonen, Mateusz Ziarkiewicz, Pawel Bernatowicz, Lidia Gil, Anna Lojko-Dankowska, Magdalena Matuszak, Jan Zaucha, Maria Czyzewska, Kamil Wisniewski, Magdalena Olszewska-Szopa, Anna Pula, Frank Wen, Frida Bugge Askeland, Valdas Peceliunas, Jennifer Cooperrider, Ken Jiang, Theodore Karrison, Benjamin Derman, Andrzej Jakubowiak
2. Dual targeting BCMA and CD19 Fastcar-t (GC012F/AZD0120) as first-line therapy for myeloma. Juan Du et al.
Novel, next day manufacturing of CART cells! Highly effective 81% sustained (12 month) MRD negative rate. Also dual targeted.
Abstract Title: A dual targeting BCMA and CD19 fastcar-t (GC012F/AZD0120) as first-line therapy for newly diagnosed multiple myeloma
Category: 600s – Hematologic Malignancy
Authors: Juan Du, Wanting Qiang, Jing Lu, Yanchun Jia, Haiyan He, Jin Liu, Pei Guo, Ying Yang, Zhongyuan Feng, Lina Jin, Xiaoqiang Fan, Nina Shah, Qi Zhang, Lianjun Shen, Jia Liu
1. Teclistamab plus Daratumumab RCT in Relapsed myeloma. Tec-3 Majestec-3
Game-changing in 3 ways -Unprecedented efficacy, HR 0.17 -Changes SOC from monotherapy to Tec-Dara -New Dara-like dosing schedule for Tec.”
Abstract Title : Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of MAJESTEC-3
Category: 600s – Hematologic Malignancy
Authors: María-Victoria Mateos, Nizar Bahlis, Aurore Perrot, Ajay Nooka, Jin Lu, Charlotte Pawlyn, Roberto Mina, Gaston Caeiro, Alain Kentos, Vania Hungria, Donna Reece, Ting Niu, Anne Mylin, Charlotte Hansen, Raphael Teipel, Britta Besemer, Meletios Dimopoulos, Elena Zamagni, Satoshi Yoshihara, Kihyun Kim, Chang-Ki Min, Paulus Geerts, Elena Van Leeuwen-Segarceanu, Agata Tyczynska, Juan Luis Reguera, Magnus Johansson, Markus Hansson, Mehmet Turgut, Mark Grey, Surbhi Sidana, Paula Rodriguez-Otero, Joaquin Martinez-Lopez, Hamza Hashmi, Robin Carson, Rachel Kobos, Weili Sun, Kristen Lantz, Anne Seifert, Debbie Briseno-Toomey, Lisa O’Rourke, Maria Rubin, Diego Vieyra, Lijuan Kang, Luciano Costa
More posts featuring Vincent Rajkumar on OncoDaily.